Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02962661 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02962661 · ClinicalTrials.gov record · last posted 2026-08-03

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

StatusSuspended
PhasePhase 1
Started2020-07-18
View on ClinicalTrials.gov ↗
Why the trial stopped
PI Request
from the ClinicalTrials.gov record
This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.

Protocol amendment history 2 changes detected by DataLookout

2026-08-04
Recruitment suspended
2026-08-04
Recruitment suspended: PI Request
Trial Details
NCT Number NCT02962661
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Enrollment 72 participants
Start Date 2020-07-18
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03